Oramed Granted Patent in China for its Platform Technology in Oral Delivery of Proteins
Oramed Granted Patent in China for its Platform Technology in Oral Delivery of Proteins PR Newswire JERUSALEM, September 10, 2013 JERUSALEM, September 10, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has received approval for a key patent from the State Intellectual Property Office of the People's Republic of China. The patent, titled "Methods and Compositions for Oral Administrations of Proteins," covers a core concept of the Company's technology. The patent has also been granted in New Zealand and South Africa. Oramed's portfolio now consists of eight issued patents and 27 patents pending. According to a report by McKinsey & Company China's healthcare sector is growing at an accelerated rate, with healthcare spending projected to grow from $357 billion in 2011 to $1 trillion by 2020. "Our platform technology in the oral delivery of proteins applies to numerous treatment markets in geographies around the globe. China is a very important market for both our ORMD-0801 and ORMD-0901 technologies," stated Oramed CEO Nadav Kidron. "As an innovative company committed to discovery, we are pleased to see our IP portfolio expand." About Oramed Pharmaceuticals Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently initiating Phase 2 clinical trials on patients with type 2 diabetes (T2DM) under an Investigational New Drug application with the U.S. Food and Drug Administration, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), with trials on healthy volunteers (Phase 1b) and T2DM patients (Phase 2a) underway. Oramed is also moving forward with clinical trials of ORMD-0801 for the treatment of type 1 diabetes. The company's corporate and R&D headquarters are based in Jerusalem. For more information, the content of which is not part of this press release, please visit http://www.oramed.com. Forward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss our clinical trials, the China market, or revolutionizing the treatment of diabetes with our products. These forward-looking statements and their implications are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission. Company Contact: Oramed Pharmaceuticals Aviva Sherman Office: +972-2-566-0001 Mobile: +972-54-792-4438 Email: firstname.lastname@example.org SOURCE Oramed Pharmaceuticals Inc.